$INCY

Incyte Corporation

  • NASDAQ
  • Health Technology
  • Biotechnology

PRICE

$97.08 ▼-0.175%

Extented Hours

VOLUME

964,226

DAY RANGE

96.92 - 98.5

52 WEEK

62.48 - 110.37

Echofin Members Consensus

SE
sebastiandv #Zona Trading Join team
recently

$AKAM $INCY $CHWY 🤑 todas andan on fire

SE
sebastiandv #Zona Trading Join team
recently

$INCY peleando el 38.2% de Fib. Retracements, aún con momentum

profile
zonatrading #Zona Trading Join team
recently

$INCY estuvo en todo!! felicidades a los que la agarraron

JA
JaviArzu #Zona Trading Join team
recently

INCY nos fue bien

profile
zonatrading #Zona Trading Join team
recently

Yo en INCY ando buscando más el multibreakout. un par de días para que consolide.

SE
sebastiandv #Zona Trading Join team
recently

@haleksander con INCY lo que veo en 4h es medias moviles y price action, si ves en la siguiente imagen toca el SMA200 y agarra tendencia al alza. Luego $95 es un nivel de soporte de casi dos meses, si lo rompe no me extrañaria que vuelva a ser el soporte. Como bien lo dijiste los indicadores dan buenas señales esperando que las EMAs de MACD esten sobre 0 para el momentum.

SE
sebastiandv #Zona Trading Join team
recently

Buenos días a todos, $INCY se ve bien en time frame D, 4h, 15min... ahorita está peleando el nivel en 95 RSI Laguerre en 15 min por cruzar y los otros time frames iniciando. Como la ven?

MA
Manglio5617 #Zona Trading Join team
recently

$INCY esta queriendo romper el triangulo

Key Metrics

Market Cap

21.14 B

Beta

0.65

Avg. Volume

1.31 M

Shares Outstanding

217.37 M

Yield

0%

Public Float

215.35 M

Next Earnings Date

2020-11-03

Next Dividend Date

Company Information

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

CEO: Hervé Hoppenot

Website:

HQ: 1801 Augustine Cut-Off Wilmington, 19803 DE

Related News

  • Delaware Business Now

    Incyte earnings beat estimates - Delaware Business Now

    04 Aug 2020, 16:42
  • Business Wire

    Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

    04 Aug 2020, 11:00
  • Benzinga

    The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings

    02 Aug 2020, 15:08
  • Seeking Alpha

    Incyte's Jakafi successful in another graft-versus-host disease study (NASDAQ:INCY)

    23 Jul 2020, 11:36
  • Business Wire

    Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints

    23 Jul 2020, 11:15